Literature DB >> 526401

Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings.

R M Pearson, D N Griffith, M Woollard, I M James, C W Havard.   

Abstract

1 Diazoxide 300 mg and labetalol 150 mg were each injected intravenously on separate occasions into five patients with essentail hypertension. The reduction in BP caused by labetalol was slightly greater than that produced by diazoxide. 2 In contrast the reduction in cerebral blood flow (CBF) by labetalol was not statistically significant, whereas diazoxide gave a greater and statistically significant reduction in CBF. 3 These observations suggest that labetalol may have an advantage over diazoxide for the rapid reduction in BP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526401      PMCID: PMC1429753     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Side effects of diazoxide.

Authors:  G K Kumar; F C Dastoor; J R Robayo; M A Razzaque
Journal:  JAMA       Date:  1976-01-19       Impact factor: 56.272

2.  Patterns of cerebral dysautoregulation in severe hypertension to blood pressure reduction with diazoxide.

Authors:  H I Goldberg; R A Codario; R S Banka; M Reivich
Journal:  Acta Neurol Scand Suppl       Date:  1977

3.  Protein binding and vascular activity of diazoxide.

Authors:  E M Sellers; J Koch-Weser
Journal:  N Engl J Med       Date:  1969-11-20       Impact factor: 91.245

4.  Hypotensive sequelae of diazoxide and hydralazine therapy.

Authors:  W L Henrich; R Cronin; P D Miller; R J Anderson
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

5.  Two minute slope inhalation technique for cerebral blood flow measurement in man. 2. Clinical appraisal.

Authors:  D J Wyper; G A Lennox; J O Rowan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-02       Impact factor: 10.154

6.  Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.

Authors:  R M Pearson; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

8.  Intravenous labetalol in hypertensive patients given by fast and slow injection.

Authors:  R M Pearson; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

9.  Autoregulation of brain circulation in severe arterial hypertension.

Authors:  S Strandgaard; J Olesen; E Skinhoj; N A Lassen
Journal:  Br Med J       Date:  1973-03-03

10.  Intradialytic measurement of cardiac output by thermodilution and impedance cardiography.

Authors:  A Handt; M O Farber; J J Szwed
Journal:  Clin Nephrol       Date:  1977-02       Impact factor: 0.975

View more
  9 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

3.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 4.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

Review 5.  Hypertension After Severe Traumatic Brain Injury: Friend or Foe?

Authors:  Vijay Krishnamoorthy; Nophanan Chaikittisilpa; Taniga Kiatchai; Monica Vavilala
Journal:  J Neurosurg Anesthesiol       Date:  2017-10       Impact factor: 3.956

Review 6.  Current management of hypertensive emergencies.

Authors:  J Y Garcia; D G Vidt
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 7.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 8.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Diazoxide and labetalol in acute hypertension during haemodialysis.

Authors:  G Keusch; H Schiffl; U Binswanger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.